- Home
- NVFY vs BLRX Comparison
NVFY vs BLRX Comparison
Compare NVFY & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVFY
- BLRX
- Stock Information
- Founded
- NVFY 2003
- BLRX 2003
- Country
- NVFY United States
- BLRX Israel
- Employees
- NVFY N/A
- BLRX N/A
- Industry
- NVFY Home Furnishings
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- NVFY Consumer Discretionary
- BLRX Health Care
- Exchange
- NVFY Nasdaq
- BLRX Nasdaq
- Market Cap
- NVFY 18.8M
- BLRX 17.0M
- IPO Year
- NVFY N/A
- BLRX 2011
- Fundamental
- Price
- NVFY $2.29
- BLRX $4.25
- Analyst Decision
- NVFY
- BLRX Strong Buy
- Analyst Count
- NVFY 0
- BLRX 2
- Target Price
- NVFY N/A
- BLRX $19.00
- AVG Volume (30 Days)
- NVFY 145.8K
- BLRX 36.3K
- Earning Date
- NVFY 08-13-2025
- BLRX 08-14-2025
- Dividend Yield
- NVFY N/A
- BLRX N/A
- EPS Growth
- NVFY N/A
- BLRX N/A
- EPS
- NVFY N/A
- BLRX N/A
- Revenue
- NVFY $9,946,300.00
- BLRX $22,340,000.00
- Revenue This Year
- NVFY N/A
- BLRX N/A
- Revenue Next Year
- NVFY N/A
- BLRX N/A
- P/E Ratio
- NVFY N/A
- BLRX N/A
- Revenue Growth
- NVFY N/A
- BLRX 91.68
- 52 Week Low
- NVFY $0.39
- BLRX $2.30
- 52 Week High
- NVFY $3.59
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- NVFY 52.68
- BLRX 43.97
- Support Level
- NVFY $1.96
- BLRX $4.47
- Resistance Level
- NVFY $3.08
- BLRX $4.75
- Average True Range (ATR)
- NVFY 0.47
- BLRX 0.30
- MACD
- NVFY -0.05
- BLRX -0.04
- Stochastic Oscillator
- NVFY 36.27
- BLRX 11.96
About NVFY Nova Lifestyle Inc.
Nova Lifestyle Inc is a designer and lifestyle furniture company. It distributes and retails contemporary styled residential and commercial furniture. The firms marketing and sales platform offers retail as well as online selection and purchase fulfillment internationally. The company also sells managed a variety of bedding foundation components. Its collection of lifestyle furniture brands includes Diamond Sofa. The firm's products are made in the United States and Asia. Its customers mainly comprise distributors and retailers having specific geographic coverages that deploy middle to high-end private label home furnishings. The company operates in one business and industry segment: the design and sale of furniture.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.